BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma

Journal of Pathology

Volumn 227, Issue 2, 2012, Pages 200-208

  Busacca, Sara ^a   Sheaff, Michael ^b   Arthur, Kenneth ^a   Gray, Steven G ^c   O'Byrne, Kenneth J ^c   Richard, Derek J ^d   Soltermann, Alex ^e   Opitz, Isabelle ^e   Pass, Harvey ^f   Harkin, D Paul ^a   Quinn, Jennifer E ^a   Fennell, Dean A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BRCA1; malignant pleural mesothelioma; resistance; vinorelbine

Indexed keywords

BRCA1 PROTEIN; NAVELBINE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRCA1 PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MESOTHELIOMA; PLEURAL NEOPLASMS; RNA INTERFERENCE; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 84860674283     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3979     Document Type: Article

References (32)

1. Fennell DA, Gaudino G, O'Byrne KJ, et al., Advances in the systemic therapy of malignant pleural mesothelioma. Nature Clin Pract Oncol 2008; 5: 136-147.
2. Fennell DA, Rudd RM,. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004; 5: 354-362.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
4. van Meerbeeck JP, Gaafar R, Manegold C, et al., Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889.
5. Steele JP, Shamash J, Evans MT, et al., Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18: 3912-3917.
6. Muers MF, Stephens RJ, Fisher P, et al., Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694.
7. Stebbing J, Powles T, McPherson K, et al., The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63: 94-97.
8. Quinn JE, Kennedy RD, Mullan PB, et al., BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228.
9. Quinn JE, James CR, Stewart GE, et al., BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13: 7413-7420.
10. Mullan PB, Quinn JE, Gilmore PM, et al., BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20: 6123-6131.
11. Tassone P, Tagliaferri P, Perricelli A, et al., BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285-1291.
12. Lafarge S, Sylvain V, Ferrara M, et al., Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20: 6597-6606.
13. Paul I, Savage KI, Blayney JK, et al., PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol 2011; 224: 564-574.
14. Papadaki C, Tsaroucha E, Kaklamanis L, et al., Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 2011; 104: 316-323.
15. Boukovinas I, Papadaki C, Mendez P, et al., Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008; 3: e3695.
16. Reguart N, Cardona AF, Carrasco E, et al., BRCA1: a new genomic marker for non-small-cell lung cancer. Clin Lung Cancer 2008; 9: 331-339.
17. Fiorentino M, Judson G, Penney K, et al., Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res 2010; 70: 3136-3139.
18. Weberpals JI, Tu D, Squire JA, et al., Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol 2011; 22: 2403-2410.
19. Swisher EM, Gonzalez RM, Taniguchi T, et al., Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 2009; 8: 48.
20. Wilson CA, Ramos L, Villasenor MR, et al., Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature Genet 1999; 21: 236-240.
21. Thrall M, Gallion HH, Kryscio R, et al., BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006; 16 (Suppl 1): 166-171.
22. Quinn JE, Carser JE, James CR, et al., BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113: 134-142.
23. Chao SK, Lin J, Brouwer-Visser J, et al., Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent. Proc Natl Acad Sci U S A 2011; 108: 391-396.
24. Bessho Y, Oguri T, Ozasa H, et al., ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep 2009; 21: 263-268.
25. Stuckler D, Singhal J, Singhal SS, et al., RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res 2005; 65: 991-998.
26. Seve P, Isaac S, Tredan O, et al., Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11: 5481-5486.
27. Rosell R, Scagliotti G, Danenberg KD, et al., Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22: 3548-3553.
28. Farmer H, McCabe N, Lord CJ, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
29. Drew Y, Mulligan EA, Vong WT, et al., Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103: 334-346.
30. Taron M, Rosell R, Felip E, et al., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449.
31. Weberpals JI, Clark-Knowles KV, Vanderhyden BC,. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 2008; 26: 3259-3267.
32. Fong PC, Boss DS, Yap TA, et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.